Shanghai Haoyuan Chemexpress Valuation

Is 688131 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688131 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688131 (CN¥37.48) is trading above our estimate of fair value (CN¥5.26)

Significantly Below Fair Value: 688131 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688131?

Key metric: As 688131 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688131. This is calculated by dividing 688131's market cap by their current earnings.
What is 688131's PE Ratio?
PE Ratio	51.8x
Earnings	CN¥152.63m
Market Cap	CN¥7.91b

688131 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.1x
Enterprise Value/EBITDA	28.7x
PEG Ratio	1.4x

Price to Earnings Ratio vs Peers

How does 688131's PE Ratio compare to its peers?

The above table shows the PE ratio for 688131 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	36.9x
688621 Beijing Sun-Novo Pharmaceutical Research	21.6x	29.5%	CN¥4.8b
688710 Shanghai Innostar Biotechnology	37x	n/a	CN¥5.4b
688046 GemPharmatech	40.6x	27.9%	CN¥5.7b
301333 R&G PharmaStudies	48.5x	27.0%	CN¥5.9b
688131 Shanghai Haoyuan Chemexpress	51.8x	37.9%	CN¥7.9b

Price-To-Earnings vs Peers: 688131 is expensive based on its Price-To-Earnings Ratio (51.8x) compared to the peer average (36.9x).

Price to Earnings Ratio vs Industry

How does 688131's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 688131 is expensive based on its Price-To-Earnings Ratio (51.8x) compared to the Asian Life Sciences industry average (31.8x).

Price to Earnings Ratio vs Fair Ratio

What is 688131's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688131 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	51.8x
Fair PE Ratio	34.5x

Price-To-Earnings vs Fair Ratio: 688131 is expensive based on its Price-To-Earnings Ratio (51.8x) compared to the estimated Fair Price-To-Earnings Ratio (34.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥51.9b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.72

7.3%

15.1%

China Resources Sanjiu Medical & Pharmaceutical

CN¥57.9b

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

999

CN¥45.11

-1.3%

19.5%